| 项目编号 |
PRJCA011295 |
| 项目标题 |
Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite |
| 涉及领域 |
Medical |
| 数据类型 |
Phenotype or Genotype
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
Vicagrel is a novel antiplatelet drug used to mitigate clopidogrel resistance due to CYP2C19 polymorphism. This study aimed to develop a semi-mechanistic population pharmacokinetic (PopPK) model to characterize the pharmacokinetic (PK) profile of M15-2, the active metabolite of vicagrel and clopidogrel, and to evaluate the influence of CYP2C19 polymorphisms and other covariates in healthy subjects and patients with acute coronary syndrome (ACS) after oral administration. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2024-08-19 |
| 出版信息 |
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Jiangsu Provincial Department of Science and Technology
|
|
BA2019055
|
|
|
|
| 提交者 |
Xiaojuan
Lai (lai_xiaojuan@vcarepharmatech.com)
|
| 提交单位 |
Jiangsu Vcare PharmaTech Co.,Ltd. |
| 提交日期 |
2022-08-18 |
